Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

[1]  A. Hauschild,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.

[2]  A. Hauschild,et al.  Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. , 2017, The Lancet. Oncology.

[3]  J. Cameron,et al.  Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma , 2016, Clinical Cancer Research.

[4]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[5]  R. Salgia,et al.  Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Hauschild,et al.  Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. , 2015, Journal of the American Academy of Dermatology.

[7]  E. Jaffee,et al.  The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[8]  Edward J. Kim,et al.  Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma , 2014, Clinical Cancer Research.

[9]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[10]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[11]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[12]  J. Berlin,et al.  A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer , 2012, Clinical Cancer Research.

[13]  S. Shankar,et al.  Sonic Hedgehog Signaling Inhibition Provides Opportunities for Targeted Therapy by Sulforaphane in Regulating Pancreatic Cancer Stem Cell Self-Renewal , 2012, PloS one.

[14]  F. Heppner,et al.  Combination of Hedgehog Signaling Blockage and Chemotherapy Leads to Tumor Reduction in Pancreatic Adenocarcinomas , 2012, Pancreas.

[15]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Reed,et al.  Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. , 2011, International journal of oncology.

[17]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[18]  Kaixing Ai,et al.  Sonic Hedgehog Expression Correlates With Distant Metastasis in Pancreatic Adenocarcinoma , 2011, Pancreas.

[19]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[20]  M. Hebrok,et al.  KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma , 2010, Nature Reviews Cancer.

[21]  A. Merchant,et al.  Targeting Hedgehog — a Cancer Stem Cell Pathway , 2010, Clinical Cancer Research.

[22]  C. Iacobuzio-Donahue,et al.  Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. , 2010, Journal of the National Cancer Institute.

[23]  A. Maitra,et al.  The hedgehog pathway and pancreatic cancer. , 2009, The New England journal of medicine.

[24]  Q. Ma,et al.  Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. , 2009, Cancer letters.

[25]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[26]  G. Feldmann,et al.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development , 2009, Molecular Cancer Therapeutics.

[27]  Thomas G. Caffery,et al.  Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer , 2008, Clinical Cancer Research.

[28]  M. Mullendore,et al.  An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer , 2008, Molecular Cancer Therapeutics.

[29]  M. Mullendore,et al.  Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer , 2008, Gut.

[30]  Hua Tian,et al.  A paracrine requirement for hedgehog signalling in cancer , 2008, Nature.

[31]  C. Iacobuzio-Donahue,et al.  Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. , 2007, Cancer research.

[32]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[33]  Yutaka Shimada,et al.  Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours , 2003, Nature.

[34]  Gregory Y. Lauwers,et al.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.

[35]  P. Ingham,et al.  Hedgehog signaling in animal development: paradigms and principles. , 2001, Genes & development.

[36]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[37]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[38]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[40]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.